Prevail Therapeutics Raises $75 Million Series A for Parkinson's Gene Therapies

Edward Kim  |

Prevail Therapeutics announced the closing of a $75 million Series A financing today to support development of gene therapies to address the underlying disease process in Parkinson’s disease and other neurodegenerative disorders. Investors in the round included OrbiMed, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners, Boxer Capital, Adage Capital Management and Alexandria Venture Investments. OrbiMed and the Silverstein Foundation for Parkinson’s with GBA incubated and provided seed funding to Prevail last year.

According to The Michael J. Fox Foundation for Parkinson's Research, an association between glucocerebrosidase (GBA1) gene mutations and Parkinson's disease was first observed in 2004. It's the most common of the currently known genetic mutations associated with Parkinson's disease, carried by up to 10% of people with the disease in the US.

Source: CNBC

Prevail’s mission to develop gene therapies that address the underlying genetic causes of neurodegenerative disease is aligned with our commitment to identify treatments that can halt the progression of Parkinson’s and other diseases. The Company has assembled an excellent team to accomplish this mission, including executive management, scientific advisors and board members, and I look forward to working with them to make a difference for patients.

- Jonathan T. Silverstein, General Partner and Co-head of Global Private Equity at OrbiMed and founder of the Silverstein Foundation for Parkinson's with GBA.

Prevail has a pipeline of AAV-based (adeno-associated virus) therapeutics targeting lysosomal dysfunction to treat patients with genetically-defined neurodegenerative diseases. The company's lead program, PR001, will be developed for a genetic subset of Parkinson’s disease and other mechanistically-related disorders.

Prevail was co-founded by Asa Abeliovich, MD, PhD, an associate professor of pathology, cell biology, and neurology at Columbia University, attending physician at New York Presbyterian Hospital and a member of the Taub Institute for Alzheimer’s Disease and the Aging Brain.

Please email us at to see our Case Studies and Testimonials.

Please click here for information on our new trading platform.

Please click here to see our weekly newsletter.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Can the Media Solve the Partisan Conflict?

Andrew McCarthy, Contributing Editor, The National Review; Michael Zeldin, CNN Legal Analyst; Celeste Katz, Senior Political Reporter, Glamour; Silvia Davi, SVP, Contributing Editor,; and Doug Simon, CEO, D S Simon Media discuss how the media’s role has shaped the landscape for communicators and what the media is trying to do to reduce discord in society.

Emerging Growth

MGX Minerals Inc.

MGX Minerals is a diversified Canadian mining company listed on the Canadian Securities Exchange. MGX is engaged in the acquisition and development of industrial mineral deposits in western Canada that…